Nutriband Secures Global Brand Name for AVERSA™ Fentanyl Patch with $80–200M Sales Potential
Nutriband has selected the worldwide commercial brand name for its lead abuse-deterrent fentanyl transdermal system and will submit the proposed labeling to FDA, other regulatory agencies and file for US and international trademark registration. The patch, built on Nutriband’s AVERSA™ technology, targets peak annual US sales of $80–$200 million.
1. Brand Name Candidate and Partnership
Nutriband engaged Brand Institute to develop and select the worldwide commercial brand name candidate for its abuse-deterrent fentanyl transdermal system. The proposed name and product labeling will be submitted for regulatory review, while trademark registration applications are being filed with the United States Patent and Trademark Office and corresponding agencies internationally.
2. Regulatory Submission Pathway
The company plans to submit the brand name and labeling dossier to the FDA under current guidance and to equivalent authorities in major markets worldwide. Drug Safety Institute, a regulatory subsidiary staffed by former global agency officials, will support naming strategy and compliance throughout the approval process.
3. AVERSA™ Abuse-Deterrent Technology
The fentanyl patch incorporates Nutriband’s AVERSA™ transdermal technology, which embeds aversive agents to deter misuse, diversion and accidental exposure. This innovation aims to balance effective pain management with enhanced safety for patients requiring opioid therapy.
4. Market Potential and Intellectual Property
Analysts project peak annual US sales between $80 million and $200 million for the abuse-deterrent patch. Nutriband’s AVERSA™ technology is protected by patents issued in 46 countries, positioning the company for market penetration across the US, Europe, Japan, Korea, China, Canada, Mexico and Australia.